BSE filing, NSE: TATVA. Summary written from the filing by ALFA Finder's alert engine.
Tatva Chintan Pharma Chem Ltd: key numbers
- Share price
- ₹1,627.80
- Market cap
- ₹3,808 Cr
- Revenue (annual)
- ₹505.9 Cr
- Net profit (annual)
- ₹42.05 Cr
- P/E (TTM)
- 60.5×Sector 34.1×
- Promoter holding
- 72.02%+0.00% QoQ
- FII holding
- 4.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tatva Chintan Pharma Chem Ltd
All →Tatva Chintan Pharma Chem Investor Presentation: Key Takeaways
Tatva Chintan reported record quarterly revenue of ₹2,173 Mn for Q2 FY27, up 76% YoY, driven by strong SDA demand. EBITDA margins remained flat at 19% due to high solvent costs and freight spikes.
Tatva Chintan Pharma Chem Q2 FY27 Results: Net Profit ₹21.5 Cr, Up 117.2% YoY
Tatva Chintan Pharma Chem Ltd reported revenue from operations of ₹217.3 Cr (+76.0% YoY) and net profit of ₹21.5 Cr (+117.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹21.5 Cr · +117.2% YoY
Tatva Chintan Pharma Chem Board Meeting Date
Tatva Chintan Pharma Chem has scheduled a Board meeting for 19 October 2026 to consider Q1 FY27 financial results. The trading window will remain closed until 48 hours after results are published.
Tatva Chintan Pharma Chem Annual General Meeting
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
Tatva Chintan Pharma Chem Credit Rating
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.
Tatva Chintan Pharma Chem Business Update
Tatva Chintan Pharma Chem Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report highlights its specialty chemicals operations and ESG metrics.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.